The FDA has recently approved a subcutaneous formulation, paving the way for increased accessibility and potential for at-home administration. This delivery method follows the successful model of diabetes and GLP-1 drugs. The approval by the FDA, announced on August 29, 2025, marks a significant development in the medical field. This new formulation offers ease of use and convenience for patients, with the potential to revolutionize healthcare delivery.